The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (<50 urn2 in-plane spatial and <100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision? 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-36
Application #
8375965
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
36
Fiscal Year
2012
Total Cost
$137,592
Indirect Cost
$54,467
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Soh, Kah Teong; Wallace, Paul K (2018) RNA Flow Cytometry Using the Branched DNA Technique. Methods Mol Biol 1678:49-77
Ramakrishnan, Swathi; Huss, Wendy; Foster, Barbara et al. (2018) Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice. Am J Clin Exp Urol 6:138-148
Chang, Han-Wen; Valieva, Maria E; Safina, Alfiya et al. (2018) Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. Sci Adv 4:eaav2131
Dong, Jing; Buas, Matthew F; Gharahkhani, Puya et al. (2018) Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology 154:1273-1281.e3
Drakhshandeh, Dori; Miller, James A; Fabiano, Andrew J (2018) Instrumented Spinal Stabilization without Fusion for Spinal Metastatic Disease. World Neurosurg 111:e403-e409
Gong, Zhihong; Wang, Jie; Wang, Dan et al. (2018) Differences in microRNA expression in breast cancer between women of African and European ancestry. Carcinogenesis :
Mahoney, Martin C; Erwin, Deborah O; Twarozek, Annamaria Masucci et al. (2018) Leveraging technology to promote smoking cessation in urban and rural primary care medical offices. Prev Med 114:102-106
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
Zonneville, Justin; Safina, Alfiya; Truskinovsky, Alexander M et al. (2018) TGF-? signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. BMC Cancer 18:670
Haring, Rodney C; Henry, Whitney Ann; Hudson, Maui et al. (2018) Views on clinical trial recruitment, biospecimen collection, and cancer research: population science from landscapes of the Haudenosaunee (People of the Longhouse). J Cancer Educ 33:44-51

Showing the most recent 10 out of 1555 publications